|
[1] Ellington A D, Szostak J W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346(6287):818-822.
[2] Tuerk C, Goid L. Systematic evoiution of ligands by exponential enrichment:RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990,249(4968):505-510.
[3] Syed M A, Pervaiz S. Advances in aptamers. Oligonucleotides, 2010,20(5):215-224.
[4] Goringer H U, Adler A, Forster N, et al. Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb Chem High Throughput Screen, 2008,11(8):16-23.
[5] Song K M, Lee S, Ban C. Aptamers and their biological applications. Sensors, 2012,12(1):612-631.
[6] Lee J H, Yigit M V, Mazumdar D, et al. Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Adv Drug Deliv Rev, 2010,62(6):592-605.
[7] Yang L, Zhang X, Ye M, et al. Aptamer-conjugated nanomaterials and their applications. Adv Drug Deliv Rev, 2011,63(14-15):1361-1370.
[8] Li X,Zhao Q, Qiu L. Smart ligand: Aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy. J Controll Release, 2013,171(2):152-162.
[9] Ashrafuzzaman M. Aptamers as both drugs and drug-carriers. Biomed Res Int, 2014,(2014):697923-697944.
[10] 杨传旭,葛志强. 以适体作为药物"靶向载体"的研究进展. 中国医药生物技术,2010, 5(4):297-299. Yang C X, Ge Z Q. Progress on aptamer as guide for targeting drug delivery. Chin Med Biotechnol, 2010, 5(4):297-299.
[11] 朱尧, 吕颖慧, 杨会勇,等. 抗病毒适体药物的研究进展. 药学学报,2013, 48 (4): 447-456. Zhu Y, Lv Y H, Yang H Y,et al. Recent progress of the aptamer-based antiviral drugs. Acta Pharmaceutica Sinica, 2013, 48 (4): 447-456.
[12] 王国庆,陈兆鹏,陈令新,等. 基于核酸适配体和纳米粒子的光学探针. 化学进展,2010,22(2-3):489-499. Wang G Q, Chen Z P, Chen L X, et al. Aptamer-nanoparticle-based optical probes. Progress in Chemistry, 2010,22(2-3):489-499.
[13] Lee J H, Jucker F, Pardi A. Imino proton exchange rates imply an induced-fit binding mechanism for the VEGF165-targeting aptamer,Macugen. FEBS Letters, 2008,582(13):1835-1839.
[14] Bates P J, Laber D A, Miller D M, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol, 2009,86(3):151-164.
[15] Reyes-Reyes E M, Teng Y, Bates P J. A new paradigm for aptamer therapeutic AS1411 action:uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res, 2010,70(21):8617-8629.
[16] Keefe A D, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov, 2010, 9(7):537-550.
[17] Kruspe S, Mittelberger F, Szameit K, et al. Aptamers as drug delivery vehicles. Chem Med Chem, 2014,9(9):1998-2011.
[18] Huang Y F, Sefah K, Bamrungsa P S, et al. Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir, 2008,24(20):11860-11865.
[19] Luo Y L, Shiao Y S, Huang Y F. Release of photoactivatable drugs from plasmonicnanoparticles for targeted cancer therapy. ACS Nano, 2011,5(10):7796-7804.
[20] Du Y Q, Yang X X, Li W L, et al. A cancer-targeted drug delivery system developed with gold nanoparticle mediated DNA-doxorubicin conjugates. RSC Advances, 2014, 4(66): 34830-30835.
[21] Zhu C L, Song X Y, Zhou W H, et al. An efficient cell-targeting and intracellular controlled-release drug delivery system based on MSN-PEM-aptamer conjugates. J Mater Chem, 2009,19(41):7765-7770.
[22] Yang X J, Liu X, Liu Z, et al. Near-infrared light-triggered,targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv Mater, 2012,24(21):2890-2895.
[23] Yu M K, Kim D, Lee I H, et al. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small, 2011,7(15):2241-2249.
[24] Meng L, Zhang X, Lu Q, et al. Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. Biomaterials, 2012,33(6):1689-1698.
[25] Zhang H J, Chen C Q, Hou L, et al. Targeting and hyperthermia of doxourubicin by the delivery of single-walled carbon nanotubes to EC-109 cells. Journal of Drug Targeting, 2013, 21(3): 312-319.
[26] Cao Z, Tong R, Mishra A, et al.Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed, 2009,48(35):6494-6498.
[27] Kang H, O'Donoghue M B, Liu H, et al. A liposome-based nanostructure for aptamer directed delivery. Chem Commun, 2010,46(2):249-251.
[28] Ara M N, Matsuda T, Hyodo M, et al. Construction of an aptamer modified liposomal system targeted to tumor endothelial cells. Biol Pharm Bull, 2014,37(11):1742-1749.
[29] Farokhzad O C, Cheng J, Teply B A, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A, 2006,103(16):6315-6320.
[30] Dhar S, Gu F X, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PlGA-PEG nanoparticles. Proc Natl Acad Sci USA, 2008,105(45):17356-17361.
[31] Athulya A, Prashanti J, Remya N, et al. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnology and Bioengineering, 2012,109 (11): 2920-2931.
[32] Li L, Xiang D, Shigdar S, et al. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. Int J Nanomedicine, 2014,21(9):1083-1096.
[33] Liu J, Liu H, Kang H,et al. Aptamer-incorporated hydrogels for visual detection,controlled drug release,and targeted cancertherapy. Anal Bioanal Chem, 2012,402(1):187-194.
[34] Bagalkot V, Zhang L, Levy-Nissenbaum E,et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett, 2007,7(10):3065-3070.
[35] Bagalkot V, Farokhzad O C, Langer R,et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed, 2006, 45(48):8149-8152.
[36] Xie L L, Tong W J, Yu D H, et al. Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery. J Mater Chem, 2012,22(13): 6053-6060.
[37] Mascini M. Aptamers and their applications.Anal Bioanal Chem,2008,390(4):987-988.
[38] Doudna J A,Cech T R,Sullenger B A.Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor.Proc Natl Acad Sci USA,1995,92(6):2355-2359.
[39] Eaton B E,Gold L,Zichi D A.Let's get specific:the relation-ship between specificity and affinity.Chem & Biol,1995,2(10):633-638.
[40] Long S B,Long M B,White R R,et al.Crystal structure of an RNA aptamer bound to thrombin. RNA,2008,14:2504-2512.
[41] Becker RC,Rusconi C,Sullenger B.Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application.Thromb Haemost,2005,93(6):1010-1201.
|
